newest glp 1 medication Comparing Ozempic, Wegovy and Other GLP-1 Drugs The Next Wave of Obesity

In December 2025, the TRIUMPH-4 trial reported that retatrutide 12 mg achieved a remarkable 28.7% mean weight loss at 68 weeks in patients with obesity and knee osteoarthritis, with substantial pain relief as well ( [71] )

Monitoring your progress and making the right call The decision to continue, reduce, or stop GLP-1 therapy should be driven by data, not arbitrary timelines or gut feelings

We believe that this 'personalization' process can bring HIMS through March, 2026, when HIMS can then start working with generic semaglutide," Larsen wrote in the analyst note

That said, if medication nonadherence was a major factor for the blunted glycemic outcomes, the question remains why GLP-1 analog therapy did mediate significant weight loss, especially in women and SSRI users